Kirsten Detrick

Kirsten Detrick, CEO, Parke-Hadley Advisors LLC

Kirsten Detrick has more than 30 years of experience as an established P&L leader, product and portfolio commercialization expert, and general manager at Fortune 10 biopharma organizations including Amgen, Bristol-Myers Squibb and Takeda. She has particular expertise in immunology, oncology, cardiovascular and rare diseases, having launched or led multibillion-dollar therapeutics including Enbrel, Entyvio, Plavix, and Prolia. Her entrepreneurial experience includes stints as CEO and CCO for seed stage and Series A start-ups. She currently serves as an Adjunct Professor at the Tuck School of Business at Dartmouth College. Kirsten regularly serves on public and private boards of directors, including roles as both member and chairman.